Gossamer Bio Inc
$ 0.18
-1.57%
05 Jun - close price
- Market Cap 41,071,800 USD
- Current Price $ 0.18
- High / Low $ 0.18 / 0.17
- Stock P/E N/A
- Book Value -0.69
- EPS -0.79
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -7.83 %
- 52 Week High 3.87
- 52 Week Low 0.16
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.46
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-18 | 2026-03-17 | 2025-11-05 | 2025-08-05 | 2025-05-15 | 2025-03-13 | 2024-11-07 | 2024-08-12 | 2024-05-07 | 2024-03-05 | 2023-11-09 | 2023-08-08 |
| Reported EPS | -0.2 | -0.21 | -0.21 | -0.17 | -0.16 | -0.15 | -0.14 | 0.22 | -0.19 | -0.21 | -0.21 | -0.45 |
| Estimated EPS | -0.188 | -0.185 | -0.19 | -0.1805 | -0.19 | -0.168 | -0.15 | 0.23 | -0.19 | -0.21 | -0.26 | -0.49 |
| Surprise | -0.012 | -0.025 | -0.02 | 0.0105 | 0.03 | 0.018 | 0.01 | -0.01 | 0 | 0 | 0.05 | 0.04 |
| Surprise Percentage | -6.383% | -13.5135% | -10.5263% | 5.8172% | 15.7895% | 10.7143% | 6.6667% | -4.3478% | 0% | 0% | 19.2308% | 8.1633% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GOSS
2026-06-05 22:08:59
Gossamer Bio (NASDAQ: GOSS) director John D. Quisel was granted 115,000 stock options as part of his board compensation. These options have an exercise price of $0.178 per share and expire on June 3, 2036. The grant is a routine non-employee director award and vests on the earlier of one year from the grant date or the next annual stockholders' meeting, contingent on his continued service.
2026-06-05 20:08:59
Gossamer Bio (NASDAQ: GOSS) director Russell J. Cox was granted 115,000 stock options at an exercise price of $0.178 per share through the company's Non-Employee Director Compensation Program. These options will fully vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting, provided Cox continues his board service. Following this transaction, Cox directly holds 115,000 stock options, which expire on June 3, 2036.
2026-06-05 20:08:59
Gossamer Bio (NASDAQ: GOSS) director Nathan Steven D was granted 115,000 stock options at an exercise price of $0.1780 per share, expiring on June 3, 2036. These options are part of the Non-Employee Director Compensation Program and will fully vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued board service. This transaction is a compensation award and not an open-market purchase, increasing his derivative securities holdings to 115,000.
2026-06-04 23:40:08
Gossamer Bio has restructured $181 million of its 2027 convertible notes through an early settlement, converting them into new 7.50% convertible senior secured first-lien notes due 2030, along with a significant issuance of common shares, prefunded warrants, and purchase warrants. This move extends debt maturity but introduces higher cash interest rates, secured debt, and potential equity dilution. The new notes include a $40 million minimum liquidity covenant, with reductions tied to future equity raises and FDA milestones.
2026-06-04 21:40:08
Gossamer Bio, Inc. (GOSS) stockholders re-elected two Class II directors, Faheem Hasnain and Russell Cox, for three-year terms and ratified Ernst & Young LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, shareholders approved, on an advisory basis, the compensation of the company’s named executive officers. These decisions were reported in an 8-K filing, detailing the vote counts for each proposal.
2026-06-04 05:10:15
Gossamer Bio, Inc. has announced the early tender results and early settlement of its exchange offer for its 5.00% Convertible Senior Notes due 2027. The company accepted $181,052,000 in principal amount, representing 90.526% of outstanding notes, for exchange into new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and prefunded/purchase warrants. This early settlement allows the company to proceed with proposed amendments to the existing indenture, eliminating restrictive covenants and certain events of default.
